APG-808 is under clinical development by Apogee Therapeutics and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APG-808’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APG-808 overview

APG808 is under development for the treatment of inflammatory, unspecified immunological diseases, asthma and chronic obstructive pulmonary disease (COPD). It acts by targeting interleukin 4 receptor subunit alpha (IL-4Ra). It is administered through subcutaneous route.

Apogee Therapeutics overview

Apogee Therapeutics (Apogee) is a preclinical stage biotechnology company that develops differentiated biologics for inflammatory and immune diseases. The company’s products pipeline includes APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb), that targets IL-13 (lebrikizumab) for the management of atopic dermatitis (AD); and APG808 targets IL-4Ra (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD). It also develops APG990 and APG222 programs to target IL-13 and OX40L for the treatment of atopic dermatitis. Apogee programs are used for various therapies including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, alopecia areata, chronic spontaneous urticaria, prurigo nodularis, and eosinophilic esophagitis. Apogee is headquartered in Waltham, Massachusetts, the US.

For a complete picture of APG-808’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.